Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
73.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (1.37%)
Market Cap: £342.04m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

New OPTIM Software and Hardware

4 Aug 2014 07:00

RNS Number : 0911O
Avacta Group PLC
04 August 2014
 



4 August 2014

Avacta Group plc

("Avacta" or the "Group")

 

 

New OPTIM Software and Hardware

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces that Avacta Analytical has completed the development of two new OPTIM variants. Alongside this, the Group has released upgraded OPTIM software, intended to widen the range of potential customers. 

OPTIM, Avacta Analytical's protein characterisation instrument, was launched during 2010 as OPTIM 1000 and was substantially redeveloped into the OPTIM2 system during 2013. Designed to reduce the time and cost of therapeutic protein development, the OPTIM instruments can provide multiple protein stability-indications at high speed using ultra-low sample volumes.

Avacta has completed the development of upgraded software for the OPTIM platform, expanding the capabilities available to end users. Two new variants to the core OPTIM platform, OPTIM 375 and OPTIM 445, which incorporate incremental measurement capabilities are now available. The Directors consider that these two new variants and the related upgraded software widen the appeal of OPTIM in its core drug development market by focusing on applications to characterise the viscosity of samples and the stability of membrane protein targets.

Alastair Smith, Avacta Group Chief Executive of Avacta said: "Now that OPTIM is becoming established as a valuable tool for protein stability characterisation, we are working hard to expand the range of applications and measurement types that the system can support in order to broaden the instrument's market appeal and drive consumable usage. The latest developments are in response to the market demand, which is growing worldwide, that we have identified for viscosity determination on small samples and for stability characterisation of membrane protein targets which are a challenging but important class of protein samples."

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel: +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Walbrook PR Ltd

Mike Wort / Anna Dunphy

Tel: +44 (0) 207 933 8780

avacta@walbrookpr.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADMGGRKMZGDZM
Date   Source Headline
17th Oct 20137:00 amRNSFirst therapeutic licensing agreement for Affimers
26th Sep 20137:00 amRNSLaunch of Sensipod - First Point of Care Test
18th Sep 20137:00 amRNSIssue of Equity and Notice of Preliminary Results
16th Sep 20137:00 amRNSNew Head of R&D Joins Avacta
2nd Sep 20135:47 pmRNSTR-1 Notification of Major Interest in Shares
29th Aug 20137:00 amRNSPre-close trading update
28th Aug 20137:00 amRNSIssue of Equity
9th Aug 20138:35 amRNSTR-1: Notification of Major Interest in Shares
7th Aug 20135:51 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:31 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:30 pmRNSTR-1: Notification of Major Interest in Shares
7th Aug 20134:00 pmRNSTR-1: Notification of Major Interest in Shares
5th Aug 201311:00 amRNSResult of General Meeting
5th Aug 20137:00 amRNSAppointment of a Non-Executive Director
25th Jul 20137:00 amRNSExpansion of Collaboration with ForteBio
18th Jul 20137:00 amRNSConditional Placing to Raise £4.7 Million
23rd May 20138:40 amRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Results
23rd Apr 20137:01 amRNSNotice of Interim Results
23rd Apr 20137:00 amRNSAppointment of Nominated Advisor and Broker
27th Feb 20137:00 amRNSInterest in Affimer Technology
27th Feb 20137:00 amRNSBusiness Update
18th Feb 20135:08 pmRNSAdditional Listing
25th Jan 20132:34 pmRNSResult of AGM
21st Jan 20131:20 pmRNSHolding(s) in Company
7th Jan 20133:47 pmRNSHolding(s) in Company
23rd Oct 20127:00 amRNSPreliminary Results
24th Sep 20127:00 amRNSAvacta and Pall extend Optim distribution to India
13th Sep 201210:24 amRNSNotice of Preliminary Results
24th Aug 20127:00 amRNSPre-close trading update
19th Jun 20125:05 pmRNSHolding(s) in Company
25th Apr 20127:00 amRNSInterim Results
2nd Apr 20127:00 amRNSAvacta Signs Exclusive Supply Deal with IDEXX
15th Mar 20127:00 amRNSNotice of Interim Results
24th Jan 201210:39 amRNSResult of AGM
19th Jan 20126:23 pmRNSHolding(s) in Company
12th Jan 201211:12 amRNSHolding(s) in Company
10th Jan 20129:26 amRNSCompletes £5.13m placing and Aptuscan acquisition
9th Jan 20124:10 pmRNSResults of General Meeting
22nd Dec 20117:00 amRNSConditional Placing and Proposed Acquisition
8th Dec 20112:20 pmRNSNotice of AGM and Report and Accounts
25th Nov 20117:00 amRNSAdditional Listing & Total Voting Rights
25th Oct 20117:00 amRNSPreliminary Results
21st Oct 20117:00 amRNSAppointment of Nomad and Broker
5th Oct 20117:00 amRNSSouth East Asian Alliance agreed with Pall
19th Sep 20117:00 amRNSNotice of Preliminary Results
9th Aug 20117:00 amRNSPre-close Trading Update
6th Jul 20117:00 amRNSChange of Registered Office
10th Jun 201112:50 pmRNSDirector/PDMR Shareholding
31st May 20117:00 amRNSAvacta secures second Optim sale in US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.